Chengdu Institute of Biological Products of China National Pharmaceutical Group Corporation (hereinafter referred to as Chengdu Institute of Sinopharm), located in Jinjiang District, Chengdu City, Sichuan Province, is one of the most important research and production bases of biologics in China, and is subordinate to China National Pharmaceutical Group Corporation (CNPGC), an important state-owned backbone enterprise managed by State-owned Assets Supervision and Administration Commission (SASAC) of the State Council.
Since its establishment in 1958, as a collaborative center for immunization in six provinces, cities and autonomous regions in southwest China, SINOPHARMA Chengdu has long been committed to the research of medical microbiology, immunology, cellular engineering and genetic engineering, and the production and operation of various types of biological products, including prophylactics, blood products, diagnostic products and genetically engineered products, which have made indelible contributions to the cause of China's immunization program. The company has made indelible contributions to China's immunization program.
In recent years, by virtue of the united, loyal and enterprising management and marketing team, excellent scientific research and development and technical guarantee ability, strict and precise production and quality consciousness, Sinopharm Chengdu maintains a good situation of healthy development. 2009, Sinopharm Chengdu has total assets of more than 1 billion yuan, the revenue from the main business excluding tax is nearly 400 million yuan, and the total profit is about 0.7 billion yuan.
GMP Chengdu has been selected as one of the top 30 largest pharmaceutical manufacturing enterprises in Sichuan Province and one of the top 10 most efficient pharmaceutical manufacturing enterprises in Sichuan Province for consecutive years. In 2007, it was selected as one of the "Four Leading Key Enterprises of Advantageous Industries" in Sichuan Province; in 2009, it was selected as one of the enterprises cultivating Chengdu's large-scale enterprises and large-scale groups, and was honored as "Innovative Pilot Enterprise of Sichuan Province". In 2009, the company was selected as the cultivating enterprise of Chengdu large enterprise group and was honored as "Innovative Pilot Enterprise of Sichuan Province".
In 2007, Sinopharm Chengdu clearly put forward the medium-term goal of "becoming a first-class domestic and internationally influential biologics enterprise in five to ten years", and accelerated the process of internationalization and scientific and technological innovation in order to realize the strategic support.
CDC has been carrying out extensive and in-depth academic exchanges and commercial cooperation with the United States, the United Kingdom, South Africa, Slovenia, India, South Korea and other countries. Jieyiwei (live attenuated B encephalitis vaccine) produced by Sinopharm Chengdu has saved more than 300 million Chinese children from B encephalitis, which has attracted a great deal of attention in the global vaccine field. Many countries expressed the hope that Sinopharm Chengdu would become their vaccine supplier, and in 2006, the product was exported to India in large quantities. In July of the same year, Sinopharm signed a cooperation agreement with PATH (Pathways for Appropriate Technology in Health) sponsored by the Gates Foundation for the live attenuated B encephalitis vaccine project. In view of the good export prospects, the cooperative project was recognized by the National Development and Reform Commission as a national high-tech industrialization project. It is expected that in 2011, Sinopharm Chengdu will become the first international vaccine supplier in China to be certified by the World Health Organization.